Medistep Healthcare IPO Listing: Strong 23% Premium Debut

Medistep Healthcare Limited, the Gujarat-based pharmaceutical products trader, made a decent debut on NSE SME on August 18, 2025. After closing its IPO bidding between August 8-12, 2025, the company commenced trading with a solid 23% premium at ₹53, exceeding market expectations and reflecting strong investor confidence in the pharmaceutical sector.

Knowledge Realty Trust Listing Details

Medistep Healthcare Limited launched its IPO at ₹43 per share with a minimum investment of 6,000 shares costing ₹2,58,000. The IPO received an overwhelming response, with a subscription of 382.14 times, individual investors at 461.11 times and NII at 289.15 times, indicating exceptional interest from retail investors in the pharmaceutical business.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

First-Day Trading Performance Outlook

Listing Price: The Medistep Healthcare share price opened at ₹53 on NSE SME, representing a premium of 23.36% from the issue price of ₹43, delivering substantial gains for investors and significantly exceeding market expectations.

Growth Drivers and Challenges

Growth Drivers:

Strong Financial Performance: Revenue increased by 27% to ₹49.66 crore in FY25 with PAT rising by 25% to ₹4.14 crore, reflecting consistent growth in pharmaceutical trading and manufacturing operations.

Diversified Product Portfolio: Comprehensive range including sanitary pads under DRYSTEP brand, energy powder under VITASTEP Z, and trading in pharmaceutical, nutraceutical, intimate care, and surgical products catering to diverse market segments.

Manufacturing Capabilities: In-house manufacturing facility in Kheda, Gujarat, for sanitary pads and energy powder, providing cost control and quality assurance advantages over pure trading businesses.

Experienced Management: Skilled promoters and management team with proven track record in the pharmaceutical industry, ensuring effective business strategy execution and market expansion.
 

Challenges:

Small Scale Operations: Relatively small revenue base of ₹49.66 crore and only nine employees, potentially restricting competitive positioning and scalability in the fragmented pharmaceutical market.

High Competition: Operating in a highly competitive pharmaceutical trading segment with price pressures and margin compression challenges affecting long-term profitability and sustainability.

Raw Material Dependencies: The Business is dependent on pharmaceutical raw material sourcing, exposing the company to price fluctuations and supply chain disruptions affecting operational efficiency.
 

Utilisation of IPO Proceeds

Working Capital Requirements: ₹12.34 crore for funding working capital needs, supporting inventory management and business operations in the pharmaceutical trading sector.

General Corporate Purposes: ₹1.64 crore for general corporate purposes supporting business operations and strategic initiatives in the pharmaceutical manufacturing sector.

Equipment Purchase: ₹0.51 crore for the acquisition of plant and machinery to expand the existing manufacturing facility, enhancing production capabilities and operational efficiency.
 

Financial Performance of Medistep Healthcare

Revenue: ₹49.66 crore for FY25, showing growth of 27% from ₹39.08 crore in FY24, reflecting strong demand for pharmaceutical products and effective business expansion.

Net Profit: ₹4.14 crore in FY25, representing growth of 25% from ₹3.33 crore in FY24, indicating stable operational performance and margin management.

Financial Metrics: Strong ROE of 29.06%, impressive ROCE of 38.91%, solid RoNW of 29.06%, healthy PAT margin of 8.35%, robust EBITDA margin of 11.27%, reasonable Price to Book Value of 2.67, and market capitalisation of ₹61.10 crore.